 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Total Revenues | |
10.6B | 12.4B | 14.3B | 14.8B | 15.0B | |
|
| Gross Profit | |
9.22B | 10.8B | 12.8B | 13.1B | 13.5B | |
|
| Operating Income | |
3.35B | 4.85B | 3.84B | 3.98B | 5.21B | |
|
| Net Income | |
2.36B | 3.67B | 2.95B | 3.17B | 4.20B | |
|
| Gross Margin | |
83.6% | 83.3% | 85.3% | 82.7% | 84.7% |   | |
| Number of Drugs in Phase I | |
8.00 | 11.0 | 15.0 | 15.0 | 13.0 | | |
| Number of Drugs in Phase II | |
11.0 | 5.00 | 11.0 | 11.0 | 14.0 | | |
| Number of Drugs in Phase III | |
5.00 | 10.0 | 8.00 | 9.00 | 10.0 | | |
| R&D/Sales Ratio | |
19.2% | 18.6% | 23.6% | 22.1% | 20.2% | | |
| Research and Development Expense | |
2.03B | 2.31B | 3.37B | 3.27B | 3.03B | | |
| ||||||
|
|
